Researchers find new trigger for onset of colon cancer, which may lead to better therapies

April 02, 2018

LEBANON, NH - Colon cancer is the second most common cause of cancer-related deaths. The APC protein has long been known for its critical role in preventing colorectal cancer. When APC is inactivated, the development of colorectal cancer is triggered. Inactivation of APC is responsible for the vast majority (80%) of all colorectal cancers. Researchers from the laboratory of Yashi Ahmed, MD, PhD at Dartmouth's Norris Cotton Cancer Center, in collaboration with the groups of Ethan Lee, MD, PhD at Vanderbilt University and David Robbins, PhD at the University of Miami's Sylvester Comprehensive Cancer Center, have identified a new function for this colon cancer gene: APC stops several colon cancer activators.

APC works in a pathway that allows one cell to communicate with its neighbors. When APC is inactivated, this pathway goes into overdrive and that triggers colon cancer development. Exactly how APC acts in this pathway has remained a mystery. The long-held view was that the sole function of APC is to cause the destruction of one activator of the overdrive activity. "The surprise from our research is that APC actually has a second role in putting the brakes on several other activators in the pathway," says Ahmed. "This work changes our view of how this key gene acts, revealing that APC's role is much broader and multi-faceted."

The team's work, "APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway" has been published as a feature article in Developmental Cell.

This new finding about the way that APC blocks the development of colorectal cancer may lead to new therapeutic targets to combat this disease. "Because this new role of APC involves proteins on the cell surface, targeting colorectal cancers may become easier," says Ahmed. "For example, therapeutic antibodies, which normally cannot work inside the cell, can now be used to treat colorectal cancers that have APC mutations."

Figuring out the exact way in which APC stops colon cancer activator proteins will hopefully allow researchers in the future to identify additional drug targets, and to better design therapies for colon cancer patients that kill cancer cells but spare the normal cells in the colon. "The discovery of the new role of APC may also help us understand why APC mutations are so prevalent in certain cancers but not others," says Lee. "Certain tissues may have a backup mechanism to put the brakes on the pathway when APC is mutated."
-end-
Yashi Ahmed, MD, PhD, is a member of the Cancer Mechanisms research program at Dartmouth's Norris Cotton Cancer Center and an Associate Professor of Molecular and Systems Biology at Dartmouth's Geisel School of Medicine.

About Norris Cotton Cancer Center at Dartmouth-Hitchcock

Norris Cotton Cancer Center combines advanced cancer research at Dartmouth's Geisel School of Medicine with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center in Lebanon, NH, at Dartmouth-Hitchcock regional locations in Manchester, Nashua and Keene, NH, and St. Johnsbury, VT, and at partner hospitals throughout New Hampshire and Vermont. It is one of 49 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.

Dartmouth-Hitchcock Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.